Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 +1.01%84 Return-on-Tangible-Asset is 6.83% as of Jun. 2026, which is 63% below its 10-year median of 18.33. GuruFocus rates BSP:BLAU3 with a GF Score™ of 84/100 and a GF Value™ of R$10.67 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Blau Farmaceutica ranks better than 70.28% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Blau Farmaceutica's annualizedNet Income for the quarter that ended in Jun. 2026 was R$214 Mil. Blau Farmaceutica's average total tangible assets for the quarter that ended in Jun. 2026 was R$3,129 Mil. Therefore, Blau Farmaceutica's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 6.83%.
The historical rank and industry rank for Blau Farmaceutica's Return-on-Tangible-Asset or its related term are showing as below:
BSP:BLAU3'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.67 Med: 18.33 Max: 31.13
Current: 7.67
During the past 10 years, Blau Farmaceutica's highest Return-on-Tangible-Asset was 31.13%. The lowest was 7.67%. And the median was 18.33%.
BSP:BLAU3's Return-on-Tangible-Asset is ranked better than 70.28% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.96
vs BSP:BLAU3: 7.67
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Blau Farmaceutica Return-on-Tangible-Asset Related Terms
Blau Farmaceutica Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.83% mean?
Blau Farmaceutica (BSP:BLAU3) has a Return-on-Tangible-Asset of 6.83% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Blau Farmaceutica and its competitors. This is 63% below median its historical median of 18.33. Over the past decade, Blau Farmaceutica's Return-on-Tangible-Asset has ranged from 7.67 to 31.13. According to the industry distribution chart, Blau Farmaceutica ranks #299 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 29.7%.
Is Blau Farmaceutica's Return-on-Tangible-Asset too high?
Blau Farmaceutica's current Return-on-Tangible-Asset of 6.83% is 63% below median its 10-year median of 18.33. Over the past 10 years, this metric has ranged from a low of 7.67 to a high of 31.13. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.96. Blau Farmaceutica's value of 6.83% is 130.7% above this industry median. Based on the distribution chart, Blau Farmaceutica ranks #299 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Blau Farmaceutica has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #299 out of 1006 companies for Return-on-Tangible-Asset. This puts Blau Farmaceutica in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.96. Blau Farmaceutica's value of 6.83% is 130.7% above this benchmark. Historically, Blau Farmaceutica's own Return-on-Tangible-Asset has ranged from 7.67 to 31.13 over the past decade. While the company's 10-year median is 18.33 vs. the industry median of 2.96, Blau Farmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.96, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current Return-on-Tangible-Asset of 6.83% is 130.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current Return-on-Tangible-Asset is 6.83%, which is 63% below median its own 10-year median of 18.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$10.67, compared to a current price of R$8.96 — trading 16% below its estimated fair value. The current Return-on-Tangible-Asset is 6.83%, which is 63% below median its 10-year median of 18.33 and 130.7% above the Drug Manufacturers industry median of 2.96. Blau Farmaceutica's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current Return-on-Tangible-Asset is 6.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.96 is trading 16% below its estimated GF Value™ of R$10.67.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
Return-on-Tangible-Asset: 6.83% (63% below median its 10-year median of 18.33)
GF Value™: R$10.67 vs. price of R$8.96 (16% below fair value)
Industry Position: 130.7% above the Drug Manufacturers median (#299 of 1006)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
84GF Score
Get the complete analysis for BSP:BLAU3
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
